FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
This study is testing a special medical device called TheraSphere GBM to see if it is safe and works well for treating a fast-growing brain tumor that has returned. The device delivers tiny radioactive beads directly to the tumor to target the cancer cells.
You may be able to join if you are 18 or older, have a confirmed diagnosis of recurrent glioblastoma, and meet specific health and tumor size requirements. Doctors will check if your tumor is in a safe location for this treatment.
Participants will receive the TheraSphere GBM treatment, which involves delivering targeted radiation directly to the tumor using tiny radioactive beads. You will also need to attend follow-up appointments and complete tests so the study team can monitor your health.
The study is currently recruiting participants at medical centers in Birmingham, Alabama, and San Diego and San Francisco, California. It is a phase 1 safety study.
- 1Tests a new device that delivers targeted radiation to brain tumors
- 2Currently recruiting patients with a returned glioblastoma
- 3Takes place at select medical centers in Alabama and California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.